FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of malignant tumor expressing ErbB2, including the administration of a therapeutic combination, in the form of a combined composition or alternately, to a mammal, where the therapeutic combination contains trastuzumab-MCC-DM1 and docetaxel, where the administration of the therapeutic combination leads to an additive effect compared to the administration of trastuzumab-MCC-DM1 or docetaxel in the form of separate remedies, where the amount of trastuzumab-MCC-DM1 is from 0.3 to 15 mg/kg, and where the amount of docetaxel is about 30 mg/kg.
EFFECT: obtaining combination of an antibody-drug conjugate and chemotherapeutic means.
10 cl, 37 dwg, 21 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| TARGETED EXPOSURE TO TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER BY HER3-TARGETED NANOPARTICLES | 2015 |
|
RU2692104C2 |
